Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

EMA committee recommends approval of Fexeric

July 27, 2015

Vidasym's phosphate binder VS-505 enters phase I/II trial

July 23, 2015

Gilead patents MAP3K5 inhibitors

July 20, 2015

ErepoXen increases hemoglobin levels to therapeutic range in phase II trial

July 16, 2015

Merck & Co. divulges ROMK channel blockers

July 15, 2015

Aquinox Pharmaceuticals reports data from LEADERSHIP trial

June 26, 2015

Eppin Pharma receives NIH grant to develop non-hormonal male contraceptive

June 19, 2015

Angion Biomedica to begin phase II trial of BB3 in acute kidney injury

June 10, 2015

Regulus Therapeutics starts phase I trial of Alport syndrome candidate RG-012

June 5, 2015

Galenica to commercialize Roche's Mircera in U.S.

May 29, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...